Reducing the risks of distortion in cannabis research
- PMID: 31491039
- DOI: 10.1111/add.14801
Reducing the risks of distortion in cannabis research
Keywords: Cannabis research; corporate lobbying; distortion; medical cannabis; research ethics; vested interests.
Comment in
-
Response to Humphreys & Hall (2020): Reducing the risks of distortion in cannabis research.Addiction. 2020 Dec;115(12):2408-2409. doi: 10.1111/add.15157. Epub 2020 Jul 3. Addiction. 2020. PMID: 32533739 No abstract available.
References
-
- Caputi T. L. Medical marijuana, not miracle marijuana: some well-publicized studies about medical marijuana do not pass a reality check. Addiction 2019; 114: 1128-1129.
-
- Bachhuber M. A., Saloner B., Cunningham C. O., Barry C. L. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med 2014; 174: 1668-1673.
-
- Alcántara A. Weedmaps wants to drive the conversation on marijuana with hundreds of billboards: installlations show positive facts about pot usage. Adweek 2018; May 7. Available at: https://www.adweek.com/digital/weedmaps-wants-to-drive-the-conversation-... (accessed 25 July 2019).
-
- Lewis A. Medical pot is our best hope to fight the opioid epidemic: ‘There are direct reasons why [cannabis] could actually help people get off of opioids,’ says one leading marijuana researcher. Rolling Stone 2017; 8 December. Available at: https://www.rollingstone.com/culture/culture-news/medical-pot-is-our-bes... (accessed 25 July 2019).
-
- Hall W. D., West R., Marsden J., Humphreys K., Neale J., Petry N. It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis. Addiction 2018; 113: 987-988.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical